Orum to begin Phase I trial of ORM-1153 after FDA clearance
The study will focus on evaluating the tolerability, safety, pharmacokinetics and pharmacodynamics of ORM-1153.
Therapy Area
Johnson & Johnson’s multiple myeloma treatment secures EC approval
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
FDA issues complete response letter to Replimune’s RP1 for melanoma
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
North Oaks opens new speciality services clinic in US
New £1bn cancer research hub planned for South London
NCCN visits Vietnam in continued cancer care collaboration
